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Hepatic steatosis, detected by hepatorenal
index in ultrasonography, as a predictor of
insulin resistance in obese subjects
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Abstract
Background: The metabolic syndrome is a worldwide health issue, with non-alcoholic fatty liver disease
(liver steatosis) being one of its features, particularly closely related to insulin resistance. This study aims to
investigate whether quantification of hepatic steatosis by abdominal ultrasonography, using hepatorenal
index, is a feasible tool for the prediction of insulin resistance, and thus the metabolic syndrome.
Methods: Patients were recruited from the Centre of Obesity at the University Hospital of North Norway,
and among participants from the Sixth Tromsø Study. Homeostasis Model Assessment of Insulin Resistance
(HOMA1-IR) was measured, body mass index (BMI, kg/m2) calculated, and hepatorenal index (HRI), i.e. the
ratio of liver to kidney optical densities, was measured by transabdominal ultrasonography. Receiver
operating characteristic (ROC) analyses were performed, detecting insulin resistance at HOMA1-IR cut-off
values >2.3 and >2.5.
Results: Ninety participants were included in the study, of which 46 (51 %) had BMI ≥30 and 27 (30 %)
had BMI ≥35. Overall, HRI at level 1.17 had sensitivity 0.90 and specificity 0.70 for predicting insulin
resistance (HOMA1-IR >2.3) in all participants. For participants with BMI ≥30, HRI at level 1.17 had sensitivity
0.94 and specificity 0.70, and for BMI ≥35, HRI at level 1.17 had sensitivity 0.93 and specificity 0.75 for
predicting HOMA1-IR >2.3. Setting the HRI limit at 1.42 gave low sensitivities and high specificities in all
BMI groups. In the analysis predicting HOMA1-IR >2.5, sensitivity values were almost the same as in the
analysis predicting HOMA1-IR >2.3, but specificity values were lower in this analysis.
Conclusion: Detection and quantification of hepatic steatosis by ultrasound and the hepatorenal index is a
feasible screening tool for identifying patients with low risk of having insulin resistance (IR, HRI <1.17),
patients at risk of having IR (HRI 1.17-1.41) and patients with likely IR (HRI ≥1.42), especially in obese
individuals.
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Background
Obesity is a major worldwide health issue due to its associ-
ation with the metabolic syndrome (MetS). In 2013, 36.9 %
of men and 38.0 % of women in developed countries were
overweight or obese [1]. Components of MetS are increased
waist circumference, hypertension, insulin resistance (IR),
type 2 diabetes and dyslipidemia, i.e. hypertriglyceridemia
and low levels of high density lipoproteins (HDL) [2, 3].
Non-alcoholic fatty liver disease (NAFLD) is closely asso-
ciated with both IR and MetS, as patients with IR run a
high risk of also having NAFLD, and NAFLD is a predictor
of the metabolic disturbances associated with MetS [4–7].
Accordingly, components of the metabolic syndrome
are also strongly associated to NAFLD in normal-weight
subjects without diabetes, and in obese subjects diag-
nosed with NAFLD the prevalence have been found to
be 67–71 % [8, 9]. Similarly, in subjects with diabetes
mellitus type 2 or impaired glucose tolerance, the preva-
lence of NAFLD is found to be 30–70 % [10–12].
The association with high body weight makes NAFLD
the most common type of liver disease in the developed
world today, with a prevalence of approximately 30 %
[13, 14], a number that is expected to increase [15].
The hepatic lipid metabolism is vulnerable to metabolic
dysfunction, resulting in the accumulation of lipid droplets
in the hepatocyte. The ‘two-hit theory’ model by Day [16]
describes the pathogenesis of NAFLD. The ‘first hit’ is a he-
patocellular lipid accumulation due to an imbalance of lipid
uptake and combustion. The progression to the ‘second hit’
is defined as a hepatocellular steatohepatitis (Non- alcoholic
steatohepatitis (NASH)), due to the imbalance between
pro- and anti-inflammatory factors [16]. Among these, adi-
pocytokines play a central role in this pathogenesis [17].
Insulin resistance is considered to be the most important
pathophysiological mechanism of MetS [18, 19]. IR is charac-
terized by impaired lowering of blood glucose through reduced
glucose uptake in muscles, and lack of insulin effect on en-
dogenous glucose production in liver. IR is also characterized
by impaired insulin effect on lipid and protein metabolism, as
well as impaired effect on a number of other organs [18, 20].
A common and efficient way of assessing insulin re-
sistance is by the Homeostasis Model Assessment of in-
sulin resistance (HOMA1-IR) [21, 22]. This model is
based on measurements of fasting blood glucose and
fasting insulin only. It has been proven to be equally
good as the gold standard for measuring IR, i.e. the
euglycemic clamp, in addition to being a more conveni-
ent test to perform. [23] A cut-off value of HOMA1-IR
>2.3 has previously been shown to have a sensitivity of
76.8 % and a specificity of 66.7 % for identifying meta-
bolic syndrome, whereas a cut-off value of 2.7 had the
same test statistics for detecting insulin resistance [24].
Measurements of increased levels of alanine amino-
transferase (ALT), aspartate aminotransferase (AST) and
gamma-glutamyl transferase (γ-GT) may be used as an
indicator of NAFLD when biopsy is contraindicated or
not available, in combination with radiological methods,
most often transabdominal ultrasonography (US) [25].
Subjective assessments of steatosis by US display a rela-
tively large inter- and intra-observer variability. A way of
reducing this variability is by measuring the liver and kid-
neys’ echogenicity on a histogram grayscale, and using the
mean values for computing the hepatorenal index (HRI)
[26]. HRI is a tool of quantifying the steatosis that is
more reliable than subjective assessment alone. In a
normal liver, HRI is in the range from 1.00 to 1.04.
Hepatic steatosis is classified as mild (HRI 1.05–1.24),
moderate (1.25–1.64) or severe (≥1.65) [26].
The availability and cost of abdominal US examina-
tions and biochemical analyses such as that of insulin by
ELISA will differ both between and within countries. In
our department, ultrasonography examinations are easily
accessible, whereas insulin measurements are not done
on a routine basis, making use of US in the assessment
of obese patients a practical approach.
As far as we know, the use of liver steatosis, assessed by
HRI at ultrasonography as a predictor and screening method
for IR, has not been examined in previous studies. Therefore,
we aimed to investigate the test properties of this method.
Aim of study
To examine whether hepatic steatosis, quantified by
HRI, is a feasible test for detecting IR.
Methods
Participants eligible for the study were adults with either
obesity or elevated liver enzymes. Only individuals meeting
the inclusion criteria were invited to participate in the study,
and all those who accepted the invitation were included.
Obese patients were recruited from the Centre of
Obesity, Department of Gastroenterology at the Univer-
sity Hospital of North Norway (n = 80). Subjects with el-
evated liver enzymes were recruited from the Sixth
Tromsø Study population (Fig. 1).
The Sixth Tromsø Study in 2008 is previously described
[27]. Participants with values of AST, ALT or γ-GT above
the Upper Limit of Normal (ULN) when examined in The
Tromsø Study (n = 68), were invited to participate in our
study. All participants who accepted the invitation were
included in the study, and divided into two groups: liver
enzymes 1–2× ULN and liver enzymes >2× ULN.
We also invited a control group with normal liver en-
zymes (n = 44), drawn from the main study population
of the sixth Tromsø Study. This control group was sized
and adjusted for sex and age to match the group of par-
ticipants with liver enzymes >2× ULN. Participants who
accepted the invitation were included in the study.
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All participants signed a written consent, which in-
cluded permission to use their data for follow-up studies.
The Regional Committee of Medical Ethics of North
Norway approved the study performed at the Centre of
Obesity, including the approval of a biobank.
The Tromsø Study organisation approved access to data
and participants for the follow-up study for the Sixth
Tromsø Study. The main ethical approval given for the
Sixth Tromsø Study by the Regional Committee of Medical
Ethics of North Norway also covered the follow-up study.
Inclusion criteria for the subjects recruited from the
Centre of Obesity were BMI >30 kg/m2 and age >18 years.
Exclusion criteria were medically treated diabetes mellitus,
severe heart disease or severe kidney failure. Patients that
met the inclusion criteria at the Centre of Obesity were in-
vited to participate in the study on their first consultation,
or at their first group seminar during their treatment
period. All participants recruited from the Centre of
Obesity underwent an Oral Glucose Tolerance Test
(OGTT), where the participants ingested 75 g of glucose
dissolved in water. Fasting and postprandial blood glucose
(mmol/L) and serum insulin (μmol/L) levels were mea-
sured at 30-min intervals for up to 180 min, and
HOMA1-IR and WBISI were calculated as follows:
Height, body weight and blood pressure were measured
[27], blood samples for measurement of liver enzymes
(AST, ALT, γ-GT) were collected, and transabdominal
ultrasonography was performed as described below.
The participants included from the Tromsø Study
follow-up were recruited from three groups: participants
with either AST, ALTor γ-glutamyl transferase >2×
Upper Limit of Normal, participants with values between
ULN and 2× ULN, and a selection of participants with
normal values, matched for sex and age of the first
group (enzyme values >2× ULN).
The group with liver enzyme levels >2× ULN was
followed up during the first few months after the
Tromsø Study visits in 2008. The two other groups were
followed up during 2013/2014. The same variables were
recorded for all three groups: height, body weight, liver
enzyme levels, and fasting blood glucose, serum insulin,
and fasting triglyceride levels. Transabdominal ultrason-
ography was performed with measurement of HRI.
Blood pressure was also measured from the Tromsø
study visits.
Transabdominal ultrasonography was performed using
a Hitachi EUB-6500 HW apparatus with a 5 MHz con-
vex EUP-C524 transducer (Hitachi Medical Corporation,
HOMA1−IR ¼ fasting glucose½   fasting insulin½ 
22:5
WBISI ¼ 10000ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
fasting glucose½   fasting insulin½   mean OGTT glucose½   mean OGTT insulin½ p
Fig. 1 Flowchart of included participants from the Sixth Tromsø Study and the University Hospital Obesity Clinic. LFT: Liver function tests (i.e. liver
enzymes), ULN: Upper limit of normal
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Tokyo, Japan). Hepatic and renal parenchymal echogenic
density on a grayscale (values 0–255) was recorded with
the built-in histogram function. An average of three re-
peated measurements was used to calculate HRI by the
formula:
HRI ¼ mean liver echogenicity
mean kidney echogenicity
Values below 1.0 were corrected to 1.0. Steatosis was
classified as mild (HRI 1.05–1.24), moderate (HRI 1.25–
1.64) or severe (HRI ≥1.65) [26].
All statistical analyses were carried out using IBM
SPSS Statistics, version 21. Receiver Operating Charac-
teristic analyses (ROC) were performed, detecting IR at
HOMA1-IR values >2.3 and >2.5 in both inclusion
groups combined.
The cut-off value HOMA1-IR >2.3 has previously been
described [24]. Other studies have previously used a
value of HOMA1-IR >2.7. In this study, the cut-off value
is set to 2.5 due to our relatively small study sample,
with few observations of HOMA1-IR >2.7.
Subgroups of the participants with BMI ≥30 (n = 46)
and BMI ≥35 (n = 27) were analysed separately.
Results
In total, 90 participants were included (20 men and 70
women), of which 22 participants were included from
the Centre of Obesity and 68 participants from the Sixth
Tromsø Study population as shown in Fig. 1. Baseline
characteristics are shown in Table 1.
For the participants included from the Centre of Obes-
ity, we calculated both HOMA1-IR and WBISI, in order
to verify the reliability of HOMA1-IR in our data set.
The correlation between HOMA1-IR and WBISI is
shown in Fig. 2.
There were five missing values for either HOMA1-IR
or HRI in the dataset. Hence, we performed the ROC
analysis with 85 participants (all cases). Sensitivity and
specificity values for different HRI levels for detecting IR
measured by HOMA1-IR are shown in Table 2. We
made the choice of cut-off values for HRI based on a
trade-off between sensitivity and specificity of the test.
The test properties and likelihood ratios derived from
the ROC analysis by 2 × 2 tables are shown in Table 3.
Overall, 45 % (n = 38) of all subjects had HRI ≥1.17,
while 13 % (n = 11) had HRI ≥1.42.
The test has a high sensitivity and a relatively low spe-
cificity for HRI values corresponding to mild hepatic
steatosis (HRI = 1.17), and a low sensitivity with a high
specificity for HRI values corresponding to moderate
hepatic steatosis (HRI = 1.42). The corresponding ROC
curves are shown in Fig. 3a–d.
Discussion
Our results show that the detection and quantification
of hepatic steatosis by the measurement of abnormal
hepatorenal index values is feasible as a screening tool
for the detection of insulin resistance. However, HRI
values corresponding to mild steatosis showed a high
sensitivity but a relatively low specificity. On the other
hand, HRI values corresponding to moderate steatosis
had a low sensitivity but a high specificity. Therefore,
one must weigh the importance of finding patients with
IR against the inconvenience of having many false posi-
tive results from the test.
Table 1 Baseline characteristics of the 90 study participants
Inclusion groups
Centre of Obesity Sixth Tromsø Study
N Median (SD) Range N Median (SD) Range
Age, years 22 43.0 (12.76) 21–69 68 66.0 (10.84) 32–82
Height, cm 22 167.5 (6.87) 156–179 68 166.0 (9.08) 141–189
Weight, kg 22 113.0 (16.13) 83.5–148.0 68 81.3 (15.51) 50.6–123.5
Systolic BP, mmHg 22 126.0 (11.36) 112–159 68 137.0 (22.07) 96–213
Diastolic BP, mmHg 22 74.0 (8.16) 62–94 68 78.0 (8.42) 50–102
BMI, kg/m2 22 41.8 (5.66) 31.8–52.7 68 28.0 (5.35) 19.3–45.6
HOMA1-IR 22 2.5 (1.75) 0.8–6.5 65 0.8 (3.18) 0.2–25.5
WBISI 22 0.3 (0.77) 0.03–2.9 0 - -
AST, U/L 22 18.0 (9.32) 12.0–53.0 66 29.5 (1.23) 14.0–71.0
ALT, U/L 4 38.5 (6.70) 29.0–45.0 66 39.0 (20.36) 14.0–102.0
γ-GT, U/L 21 29.0 (45.72) 13.0–198.0 65 82.0 (82.74) 14.0–398.0
ALP, U/L 4 88.0 (9.22) 80.0–99.0 66 81.0 (38.96) 36.0–322.0
SD Standard Deviation, BP Blood Pressure, BMI Body Mass Index, HOMA1-IR Homeostasis Model Assessment of Insulin Resistance 1, WBISI Whole Body Insulin
Sensitivity Index, AST Aspartate Aminotransferase, ALT Alanine Aminotransferase, γ-GT Gamma-Glutamyl Transferase, ALP Alkaline Phosphatase
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As far as we know, the relationship between an abnor-
mal HRI and abnormal HOMA1-IR values has not been
investigated before, despite the invariable association be-
tween NAFLD, obesity and MetS [5]. In light of this as-
sociation, having good screening methods for detecting
early signs of MetS, especially in obese patients, is of
great importance. Also in normal-weight subjects at risk,
a good screening tool is useful. In normal-weight and
non-diabetic individuals the correlation between the
components of MetS, visceral fat accumulation and IR
Fig. 2 Correlation between WBISI and HOMA-IR for 22 overweight or obese participants. Spearman’s corr. 0.862 (p <0,001). Spearman Correlation:
−0.922 (p <0.001) (two-tailed analysis)
Table 2 Test properties for different levels of hepatorenal index for the prediction of insulin resistance (HOMA1-IR)
HOMA-IR >2.3
All participants (n = 85)
(n = 21 with HOMA-IR >2.3)
BMI ≥30 (n = 45)
(n = 18 with HOMA-IR >2.3)
BMI ≥35 (n = 27)
(n = 15 with HOMA-IR >2.3)
HRI cut-off 1.17 1.42 1.17 1.42 1.17 1.42
Sensitivity 0.90 (.71; .97) 0.33 (.17; .55) 0.94 (.74; .99) 0.33 (.16; .56) 0.93 (.70; .99) 0.27 (.11; .52)
Specificity 0.70 (.58; .80) 0.94 (.85; .98) 0.70 (.52; .84) 0.96 (.82; .99) 0.75 (.47; .91) 0.92 (.65; 99)
LR + 3.05 (2.04; 4.56) 5.33 (1.73; 16.4) 3.19 (1.76; 5.76) 9.0 (1.18; 68.6) 3.73 (1.39; 10.0) 3.20 (.41; 25.0)
LR - 0.14 (.04; .51) 0.71 (.52; .97) 0.08 (.01; .54) 0.69 (.50; .97) 0.09 (.01; .61) 0.80 (.56; 1.14)
HOMA-IR >2.5
All participants (n = 85)
(n = 17 with HOMA-IR >2.5)
BMI ≥30 (n = 45)
(n = 14 with HOMA-IR >2.5)
BMI ≥35 (n = 27)
(n = 12 with HOMA-IR >2.5)
HRI cut-off 1.17 1.42 1.17 1.42 1.17 1.42
Sensitivity 0.88 (.66; .97) 0.29 (.13; .53) 0.93 (.69; .99) 0.29 (.12; .55) 0.92 (.56; .99) 0.18 (.05; .48)
Specificity 0.66 (.54; .76) 0.94 (.82; .94) 0.61 (.44; 76) 0.90 (.75; 97) 0.60 (.36; .80) 0.81 (.57; .93)
LR + 2.61 (1.79; 3.80) 4.85 (1.15; 9.63) 2.40 (1.51; 3.82) 2.95 (.76; 11.4) 2.29 (1.21; 4.36) 0.97 (.19; 4.88)
LR - 0.18 (.05; .66) 0.75 (.57; 1.06) 0.12 (.02; 79) 0.79 (.56; 1.12) 0.14 (.02; 95) 1.01 (.70; 1.45)
Test properties and likelihood ratios (LR ±) for different cut-off values of hepatorenal index (HRI) for predicting different levels of insulin resistance, defined by
Homeostasis Model Assessment of Insulin Resistance (HOMA1-IR) >2.3 and 2.5, respectively. BMI subgroups are analysed specifically
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has shown to correlate with the severity of NAFLD and all
the different components of MetS are strongly associated
with NAFLD [8, 28]. Transabdominal ultrasonography
(US) is already in use for bedside diagnostics of NAFLD,
but subjective evaluation of steatosis characteristics in US
is susceptible to inter and intra observer variability, espe-
cially for mild and moderate steatosis [25]. Our results in-
dicate that the use of HRI will improve the test properties
of US in the diagnostics of MetS.
IR in obese individuals is crucial for the risk of further
development of MetS, and the presence of hepatic steatosis
and IR is closely linked. Although the HOMA1-IR is rela-
tively simple to calculate both in general practice and in
specialist care, it tends not to be in mind of the clinician,
unless there are other factors suggesting an underlying IR.
A previous study by Geloneze et al. has shown that the
optimal cut-off value of HOMA1-IR is 2.3 for detecting in-
sulin resistance and MetS (sensitivity 77 % and specificity
67 %) [24]. The updated HOMA2-IR is more accurate, cor-
recting for feedback relationships between insulin resis-
tances in different organs [24]. The optimal cut-off value for
HOMA2-IR is 1.4, (sensitivity 79 % and specificity 62 %).
However, HOMA2-IR has a limited range of reliable values,
and calculating the index is much more complicated [24].
A second method for assessing IR is the Whole Body
Insulin Sensitivity Index (WBISI), which adds predictive
value to HOMA-IR for assessing risk of IR, but is more
inconvenient to use in clinical practice because of the
need of an Oral Glucose Tolerance Test (OGTT), meas-
uring postprandial blood glucose and serum insulin
values in addition to fasting levels [23, 29]. We have
demonstrated a good correlation between WBISI and
HOMA1-IR, and thus the usefulness of HOMA1-IR in
this study.
Our cut-off value of HOMA1-IR >2.3 was set in
accordance to the study by Geloneze et al. [24]. Our re-
sults show that using HRI as a screening test for detect-
ing IR is possible, but it should only be used in groups
where the prevalence of IR is high, that is, in people with
BMI >30. In this group, mild steatosis (HRI ≥1.17) diag-
nosed by ultrasonography, detected 94 % of patients
with a HOMA1-IR of more than 2.3. However, the spe-
cificity of the test is low (70 %). Therefore, this test will
identify patients with high risk of having IR.
We also calculated test properties for HOMA-IR level
2.5, because the clinical significance of the HOMA1-IR
limit may vary, depending on whether one is interested
in a high sensitivity or a high specificity of HOMA1-IR
in diagnosing patients with true IR [24]. A limit of 2.5
gives a more clinically applicable HOMA-IR value, but
with a higher number of false negative results.
The gold standard for diagnosing hepatic steatosis is
by liver biopsy [30], which also is the only way of diag-
nosing the presence of steatohepatitis. Liver biopsy,
however, remains an invasive procedure with a risk of
complications, and the need for biopsy in the diagnosis
of NAFLD is much debated [31]. Ultrasonography, being
a risk-free non-invasive procedure, that is simple to per-
form, would be a good choice for clinical screening.
In a previous study of the test properties of HRI per-
formed during abdominal ultrasonography, it was shown
that a HRI cut-off value of 1.49 has a sensitivity of
100 % and a specificity of 91 % for detecting a 5 % stea-
tosis, diagnosed by liver biopsy [26]. Our results show
that a HRI cut-off at 1.42 will have a specificity of 96 %
in the obese group with BMI ≥30 for having HOMA1-IR
>2.3. A HRI value ≥1.49 will therefore be diagnostic, for
both having an actual hepatic steatosis, and also actually
having a HOMA1- IR of more than 2.3, and thus having
insulin resistance.
Although a lower HRI cut-off level of ≥1.17 will give
many false positive results, this is acceptable in a screen-
ing test, since the verification of IR is relatively simple
through calculating HOMA1-IR.
One of the strengths of this study is that the study
population is similar to the patient group that will be
relevant for this screening, both in regards to overweight
and obesity, as well as pathological liver enzyme levels.
An extrapolation to the general population is, however,
not possible.
We did not perform liver biopsy to confirm the results
of the ultrasound examination. Therefore, one cannot
Table 3 2 × 2 tables for detecting insulin resistance




HRI ≥1.17 19 19 38
<1.17 2 45 47




HRI ≥1.17 17 8 25
<1.17 1 19 20




HRI ≥1.17 14 3 17
<1.17 1 9 10
Total 15 12 27
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say that participants with HRI ≥1.49 have hepatic steato-
sis. The correlation between the actual steatosis and IR
is beside the scope of this study, since this correlation is
generally accepted [13].
One of the weaknesses of using HRI as a means of
assessing steatosis is its variability. There is a certain de-
gree of both inter- and intra-observer variability, but the
results are also dependent on the type of ultrasound
equipment used. An example of this is one of the fea-
tures available in later ultrasonography equipment
models, i.e. the option to highlight the liver tissue above
other tissues. Thus, the actual HRI values in different
studies may not be directly comparable as a result, and
one needs to be aware of this as a source of bias when
choosing this method.
The participants were not examined for other chronic
liver diseases, apart from a medical history. This is a
possible source of bias, since the presence of liver cir-
rhosis could influence the HRI measurements.
The small sample size is a weakness of this study, particu-
larly in the subgroup of morbid obese participants (BMI ≥
35), where only 12 participants had HOMA1-IR >2.3.
Fig. 3 a ROC curve of HOMA-IR >2.3 by HRI in participants with BMI ≥30. b ROC curve of HOMA-IR >2.3 by HRI in participants with BMI ≥35. c
ROC curve of HOMA-IR >2.5 by HRI in participants with BMI ≥30. d ROC curve of HOMA-IR >2.5 by HRI in participants with BMI≥ 35
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Because of this, the results of our study need confirm-
ation by further studies, with more participants included.
Conclusion
The detection of hepatic steatosis by transabdominal
ultrasound, and the quantification of steatosis by measure-
ment of the hepatorenal index, is a feasible screening tool
for stratifying patients with regards to risk of having insu-
lin resistance: patients with low risk of IR (HRI <1.17), pa-
tients at risk of having IR (HRI 1.17–1.41), and patients
with likely IR (HRI ≥1.42). The test should primarily be
used in obese subjects.
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